Summary: Why $5.06 Is The Price Per Share That Makes MannKind Traders A Lot Of Money. Why $6.06 Is The Price Per Share That Makes MannKind Shorts A Lot Of Money. One Look Into How To Trade MannKind And Why Traders Trade This Stock. If an investor bought 10,000 shares of MannKind Corporation (NASDAQ:MNKD) on … Read more
MannKind Corporation (NASDAQ: MNKD) | Sanofi SA (ADR) (NYSE: SNY) If you follow my writing here or elsewhere, you know that MannKind stock is one of my favorite topics. The company developed an inhaled insulin called Afrezza that I have high hopes for; and that’s where Sanofi comes in. When it comes to Afrezza, it’s … Read more
MannKind Corporation (NASDAQ: MNKD) After a bullish run that lasted about 3 weeks, MannKind has had a tough week in the market this week. However, as I’ve mentioned since the stock started downtrends, I wasn’t too concerned. As a matter of fact, I saw the declines as an opportunity; and it looks like today is … Read more
MannKind Corporation (NASDAQ: MNKD) MannKind Corporation has been an incredibly interesting stock to watch recently. After struggling a few months back thanks to a Goldman Sachs downgrade; a research note from Jefferies sent the stock back in bullish mode over the past couple of weeks. However, this week has been a bit of a different … Read more
MannKind Corporation (NASDAQ: MNKD) If you follow CNA Finance or my writing elsewhere, you probably already know that MannKind is and has been one of my favorite biotech stocks for quite some time. While I may have gotten a bit of backlash for my opinion on MNKD in the past; it’s clear that recently, investors … Read more
MannKind Corporation (NASDAQ: MNKD) If you’ve been following CNA Finance or my writing elsewhere, you know that one of my favorite stocks to follow in biotech is MannKind. While the stock was having a bit of a hard time a few months ago, that doesn’t seem to be the case recently. As a matter of … Read more
MannKind Corporation (NASDAQ: MNKD) This article was originally featured at Warrior Trading News. MannKind has had a bit of a troubling time in the market over the last few months. However, a recent news release by Jefferies helped to prop the stock back up. Then a new member was elected to the board; resulting in … Read more
Hey everyone, sorry for the short break in posts this morning. Just after posting this morning’s article on MannKind, I got a call from one of our amazing readers by the name of Russel to talk about MNKD, Afrezza, and more. While the conversation first started with MannKind, we ended up talking about how many … Read more
MannKind Corporation (NASDAQ: MNKD) MannKind stock has been back on the rise recently after the months of declines we saw following the unfounded Goldman Sachs downgrade. Earlier in the month, Jefferies publsihed the results of a survey that showed that physicians haven’t just heard about Afrezza, but they’re likely to start using it more in … Read more
MannKind Corporation (NASDAQ: MNKD) MannKind Corporation has had a bit of a hard time over the past few months. However, about 2 weeks ago, that all changed as a Jefferies research note showed that 65% of the endocrinologists they surveyed stated that they not only knew about Afrezza, but plan to start using it more … Read more